Journal of Hepatology最新文献

{"title":"Evaluating the translational feasibility and safety of IL-22 driven long-term hepatocyte expansion.","authors":"Katie Harrison, Jessica Nulty, Eirini Kyrana, Anil Dhawan","doi":"10.1016/j.jhep.2026.08.007","DOIUrl":"10.1016/j.jhep.2026.08.007","url":null,"abstract":"","PeriodicalId":15888,"journal":{"name":"Journal of Hepatology","volume":" ","pages":""},"PeriodicalIF":40.1,"publicationDate":"2026-08-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148764744","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Evaluating the Limitations of Hepatic SIDT1 and DTWD2 as Indicators of Impaired GlycoRNA Biogenesis in MASLD","authors":"He Zhang, Shaoli Wang","doi":"10.1016/j.jhep.2026.07.032","DOIUrl":"https://doi.org/10.1016/j.jhep.2026.07.032","url":null,"abstract":"","PeriodicalId":15888,"journal":{"name":"Journal of Hepatology","volume":"29 1","pages":""},"PeriodicalIF":25.7,"publicationDate":"2026-08-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148715538","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Non-selective Beta-Blockers in Cirrhosis and AKI: Time to Reconsider Routine Withdrawal?","authors":"Gemma Wells, Alastair O’Brien","doi":"10.1016/j.jhep.2026.08.005","DOIUrl":"https://doi.org/10.1016/j.jhep.2026.08.005","url":null,"abstract":"","PeriodicalId":15888,"journal":{"name":"Journal of Hepatology","volume":"11 1","pages":""},"PeriodicalIF":25.7,"publicationDate":"2026-08-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148715537","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Reply to: \"Prior surveillance can bias cross-sectional validation of novel HCC biomarkers: Incumbent test bias\".","authors":"David J Taggart, Scott D Barnett, Mindie H Nguyen","doi":"10.1016/j.jhep.2026.08.001","DOIUrl":"10.1016/j.jhep.2026.08.001","url":null,"abstract":"","PeriodicalId":15888,"journal":{"name":"Journal of Hepatology","volume":" ","pages":""},"PeriodicalIF":40.1,"publicationDate":"2026-08-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148697614","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Reply to: Correspondence on 'Integrative omics and phase IIa clinical trial identify TNF as key node in autoimmune hepatitis': Anti-TNF therapy in autoimmune hepatitis: We should move faster.","authors":"Johannes Hartl, Jan Philipp Weltzsch, Marcial Sebode, Christoph Schramm, Ansgar Wilhelm Lohse","doi":"10.1016/j.jhep.2026.07.027","DOIUrl":"10.1016/j.jhep.2026.07.027","url":null,"abstract":"","PeriodicalId":15888,"journal":{"name":"Journal of Hepatology","volume":" ","pages":""},"PeriodicalIF":40.1,"publicationDate":"2026-08-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148678737","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Corticosteroid therapy for drug-induced liver injury: Mind the gap!","authors":"Guruprasad P Aithal, Sabine Weber, Hester Franks","doi":"10.1016/j.jhep.2026.07.023","DOIUrl":"10.1016/j.jhep.2026.07.023","url":null,"abstract":"<p><p>Idiosyncratic drug-induced liver injury (DILI) resolves following discontinuation of the causative drug in about 80% of individuals. However, liver injury may persist beyond 6 months in 10%-15% of patients, and about 10% die within 2 years of DILI onset. DILI may progress to liver failure even after withdrawal of the offending medication in up to 10% of patients. Consequently, corticosteroids, because of their anti-inflammatory properties, have been used to prevent progression of DILI. With the advent of highly effective checkpoint inhibitors for the treatment of a variety of cancers, corticosteroids are increasingly used at high doses with the intention of accelerating resolution of liver injury. However, there is no evidence that corticosteroids hasten resolution of acute liver injury or reduce the risk of death or liver transplantation in acute DILI. In fact, corticosteroids can impair tissue repair and regeneration and may induce resistance, particularly when used at high doses for prolonged periods to treat checkpoint inhibitor-induced liver injury (ChILI). Indeed, their use has been associated with delayed resolution of ChILI and increased adverse effects. When used to treat immune-related adverse events within 2 months of initiating checkpoint inhibitors across a wide range of cancers, corticosteroids have even been associated with reduced overall survival. Corticosteroid-sparing approaches appear to be safe and effective in the majority of patients with ChILI. A modest dose of prednisolone, tapered over 4 weeks, may be considered selectively in patients with ChILI when bilirubin continues to rise after withdrawal of the checkpoint inhibitor, liver histology demonstrates marked ongoing necroinflammation, and cholestasis or cholangiopathy has been excluded.</p>","PeriodicalId":15888,"journal":{"name":"Journal of Hepatology","volume":" ","pages":""},"PeriodicalIF":40.1,"publicationDate":"2026-08-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148678725","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"OSM-STAT3 signaling facilitates Long-term expansion of Pediatric Hepatic Organoids","authors":"Yahui Li, Ying Wang, Ying Lu, Wei Cai, Yongtao Xiao","doi":"10.1016/j.jhep.2026.07.025","DOIUrl":"https://doi.org/10.1016/j.jhep.2026.07.025","url":null,"abstract":"","PeriodicalId":15888,"journal":{"name":"Journal of Hepatology","volume":"21 1","pages":""},"PeriodicalIF":25.7,"publicationDate":"2026-08-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148693191","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Reproducibility of biomarkers in MASLD: A benchmark for clinically meaningful change in serially measured non-invasive tests.","authors":"Tsz Yuen Au, Amanda Darekar, Vincent Wai-Sun Wong, Julie Foucquier, Celine Fournier, Neeta B Amin, Quentin M Anstee","doi":"10.1016/j.jhep.2026.07.029","DOIUrl":"10.1016/j.jhep.2026.07.029","url":null,"abstract":"<p><strong>Background & aims: </strong>The use of non-invasive tests (NITs) to monitor disease severity in metabolic dysfunction-associated steatotic liver disease (MASLD) necessitates a clear understanding of clinically meaningful changes at the patient level. This study assessed the measurement variation of NITs in the pre-randomisation screening pipeline of a phase II clinical trial in patients with biopsy-confirmed at-risk MASLD.</p><p><strong>Methods: </strong>This study was conducted across 198 centres in 11 countries. The screening analysis set (ScrAS) (n = 803) comprised patients screened for trial entry with an evaluable biopsy for eligibility assessment. The randomised analysis set (RAS) (n = 255) comprised participants with histologically confirmed at-risk steatohepatitis that fulfilled all trial entry criteria and represents a more highly characterised subset nested within the larger ScrAS dataset. Multiple NITs (including vibration controlled transient elastography [LSM-VCTE], enhanced liver fibrosis test [ELF], PRO-C3, ADAPT, PRO-C6, CK-18 M30/M65) were evaluated for measurement variation, with results reported as within-subject % coefficient of variation (wCV) and reproducibility coefficient % (RDC).</p><p><strong>Results: </strong>The analysis of ScrAS demonstrates that LSM-VCTE exhibits a wCV of 19.9%, with a corresponding RDC of 55.2%. LSM-VCTE in RAS shows a wCV of 23.0% and RDC of 63.8%. While controlled attenuation parameter had the lowest wCV (8.8% in ScrAS; 8.7% in RAS) and RDC (24.2% in ScrAS; 24.1% in RAS) of the FibroScan-derived parameters, ELF demonstrated the lowest wCV (3.4%) and RDC (9.3%) overall.</p><p><strong>Conclusions: </strong>These data provide a clear and robust measure of reproducibility for a range of widely adopted NITs, providing insights into the magnitude of biomarker change that may be biologically meaningful and thereby informing both longitudinal monitoring of disease progression in clinical practice and assessment of treatment response in therapeutic trials.</p><p><strong>Clinicaltrials: </strong>gov (NCT#04321031).</p><p><strong>Impact and implications: </strong>The lack of disease-specific biomarker reproducibility data has hampered the adoption of non-invasive tests (NITs) for longitudinal monitoring of disease natural history in clinical practice, and has hindered the regulatory adoption of NITs as tractable surrogate endpoints to support drug development, as it leads to uncertainty about what magnitude of biomarker change indicates genuine disease progression. The present study addresses both these challenges by providing a clear and robust measure of reproducibility for a range of widely adopted NITs, generating actionable data that facilitate longitudinal monitoring of disease progression and treatment response.</p>","PeriodicalId":15888,"journal":{"name":"Journal of Hepatology","volume":" ","pages":""},"PeriodicalIF":40.1,"publicationDate":"2026-08-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148669355","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Metabolic dysfunction profiles identify heterogeneous hepatocellular carcinoma risk in MASLD-associated advanced fibrosis.","authors":"Mario Romeo, Marcello Dallio, Carmine Napolitano, Fiammetta Di Nardo, Alessandro Federico","doi":"10.1016/j.jhep.2026.07.026","DOIUrl":"10.1016/j.jhep.2026.07.026","url":null,"abstract":"","PeriodicalId":15888,"journal":{"name":"Journal of Hepatology","volume":" ","pages":""},"PeriodicalIF":40.1,"publicationDate":"2026-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148653952","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A WHA resolution on steatotic liver diseases - A global call to action.","authors":"Khaled Abdel Ghaffar, El Amira Rashwan, Mohamed Hassany","doi":"10.1016/j.jhep.2026.07.024","DOIUrl":"10.1016/j.jhep.2026.07.024","url":null,"abstract":"","PeriodicalId":15888,"journal":{"name":"Journal of Hepatology","volume":" ","pages":""},"PeriodicalIF":40.1,"publicationDate":"2026-07-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148648639","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}